Anti-type 2 monoclonal antibody therapy for eosinophilic COPD beyond triple therapy: a systematic review and meta-analysis with strict eosinophil inclusion criteria.
Type 2 monoclonal antibodies cut moderate-to-severe exacerbations in eosinophilic chronic obstructive pulmonary disease
Anti-type 2 monoclonal antibody therapy for eosinophilic COPD beyond triple therapy: a systematic review and meta-analysis with strict eosinophil inclusion criteria.
As a heterogeneous disease, chronic obstructive pulmonary disease (chronic obstructive pulmonary disease) presents with eosinophil driven type 2 inflammation in some patients.
This study searched 8 databases from inception to March 17, 2026, for randomized controlled trials (randomized controlled trials) comparing type 2 mAbs vs. placebo in eosinophilic chronic obstructive pulmonary disease, defined as a blood eosinophil count (blood eosinophil count) ≥300 cells/μL.
type 2 antibodies cut moderate to severe flare ups versus placebo
Among secondary outcomes, pre-bronchodilator FEV 1 improved by 61.97 mL (95% CI 5.09 to 118.85).
SGRQ score decreased by -3.16 points (95% CI -4.54 to -1.79).
E-RS: chronic obstructive pulmonary disease score decreased by -0.67 points (95% CI -1.20 to -0.14).
There was no statistically significant difference between the treatment group and placebo group in the incidence of adverse events.
In eosinophilic chronic obstructive pulmonary disease patients, type 2 mAbs reduce moderate-to-severe exacerbations without additional safety signals.
Improvements in lung function and quality of life were statistically significant but modest. The symptom benefit was also statistically significant, but should be interpreted with caution given the non-robust sensitivity analysis.
This evidence supports the use of type 2 mAbs as an add on treatment for these patients.